POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia.

doi:10.1182/bloodadvances.2025017751

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia.

Blood advances - 14 Apr 2026

Zanwar Saurabh, Abeykoon Jithma, D'Sa Shirley, Roos-Weil Damien, Larson Dirk R, Colby Colin L, Durot Eric, Kastritis Efstathios, Uppal Encarl, Tomkins Oliver, Morel Pierre, Mondello Patrizia, Montes Lydia, Paludo Jonas, Ailawadhi Sikander, Sarosiek Shayna, Ogunbiyi Olabisi, Cornillet-Lefebvre Pascale, Rajkumar S Vincent, Quinquenel Anne, Dispenzieri Angela, Fonseca Rafael, Gertz Morie A, Kumar Shaji, Dimopoulos Meletios A, Ansell Stephen M, Treon Steven, Castillo Jorge J, Kapoor Prashant

Abstract excerpt

ABSTRACT: Waldenström macroglobulinemia (WM) is characterized by recurrent MYD88 and CXCR4 mutations, whose prognostic value in patients treated with chemoimmunotherapy remains unclear. Moreover, the typically prolonged progression-free survival (PFS) correlates inconsistently with overall survival (OS), underscoring the importance of examining other surrogates. Progression of disease within 24 months (POD24), an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Disease Progression

Share to Myeloid Differentiation Factor 88

Share to Prognosis

Share to Receptors, CXCR4

Share to Rituximab

Share to Waldenstrom Macroglobulinemia

Source

Open in PubMed Open full text

Identifiers

PMID: 41499755
DOI: 10.1182/bloodadvances.2025017751
PMCID: PMC13066950

Genes

CXCR4
MYD88

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

POD24 is a novel determinant of prognosis in patients with Waldenström macroglobulinemia.PMID 41499755Read ↗

Toward personalized treatment in Waldenström macroglobulinemia.Semantic proximity Read ↗

Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia.Semantic proximity Read ↗

Waldenström macroglobulinemia.Semantic proximity Read ↗

Clinico-pathologic characteristics, patterns of treatment and outcome of newly diagnosed Waldenströms Macroglobulinemia- a single center real world retrospective analysisSemantic proximity Read ↗

Waldenstrom macroglobulinemia: genetics dictates clinical course.Semantic proximity Read ↗

Current approach to Waldenström Macroglobulinemia.Semantic proximity Read ↗

Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.Semantic proximity Read ↗

Prognostic significance of clinical risk models and genomic alterations in Waldenström macroglobulinemia before or after the BTK inhibitor era.Semantic proximity Read ↗

Advances in Treatment of Waldenström Macroglobulinemia.Semantic proximity Read ↗

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.Semantic proximity Read ↗

Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.Semantic proximity Read ↗

How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.